Today 2026.09.21 D-End
Today 
|
[OP01] Oral Presentation 1 |
Room A (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Yeon Jung Lim (Chungnam National University College of Medicine, Korea) Seok Lee (Ewha Womans University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Distinct Genetic Architecture and Integrated Risk Stratification in Adult ETP-ALL and Other T-ALL Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | Phase 2 Study Results; Clinical Outcomes of Adults with Ph-Positive ALL Treated with Frontline Ponatinib Plus Hyper-CVAD Followed by RTC-Allo-HCT Incorporating ATG/PTCy with Ponatinib Prophylaxis Jong Hyuk Lee (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:20-09:30 | Inotuzumab Ozogamicin as Salvage Therapy Prior to Second Allogeneic Hematopoietic Cell Transplantation Reduces Relapse without Increasing Non-Relapse Mortality in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Joon Young Hur (University of Ulsan College of Medicine, Korea) | ||
| 09:30-09:40 | TAL1 Activation Mechanisms Stratify Relapse Risk and Identify a High-Risk Subgroup Unresponsive to HSCT in Pediatric T-ALL Senlin Zhang (Children's Hospital of Soochow University, China) | ||
| 09:40-09:50 | Genomic Landscape and Clinical Outcomes of MTAP Rearrangements in Pediatric T-Cell Acute Lymphoblastic Leukemia: A Retrospective Cohort Study Shier Cheng (Children's Hospital of Soochow University, China) | ||
| 09:50-10:00 | Successful Transplant-Sparing Management of EBF1: PDGFRB-Positive Ph-like Acute Lymphoblastic Leukemia Using Imatinib and CD19 CAR-T Therapy with Prolonged TKI Maintenance Hina Nakajima (Chiba University Hospital, Japan) | ||
|
[OP02] Oral Presentation 2 |
Room B (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Jeong A Kim (College of Medicine, The Catholic University of Korea, Korea) Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Multi-Trajectories of Lipid Profiles and Their Association with Clinical Outcomes in AML Patients Undergoing Allo-HSCT Hongru Chen (Peking University People's Hospital, China) | |
| 09:10-09:20 | High Frequency of Extramedullary Relapse in Very Late Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation Jin-Hee Han (University of Ulsan College of Medicine, Korea) | ||
| 09:20-09:30 | Comparable Post-Transplant Outcomes Following Intensive Chemotherapy versus Hypomethylating Agent plus Venetoclax before First Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Hyunkyung Park (University of Ulsan College of Medicine, Korea) | ||
| 09:30-09:40 | Efficacy and Safety of Venetoclax and Azacitidine Maintenance in Reducing Relapse after Haploidentical HSCT for Pediatric AML: A Retrospective Two-Center Cohort Study He Hongbo (Beijing Children's Hospital, China) | ||
| 09:40-09:50 | Venetoclax plus Hypomethylating Agents for Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation Jiseon Park (University of Ulsan College of Medicine, Korea) | ||
| 09:50-10:00 | HCT-CI Failed to Predict Survival Outcomes in Elderly Patients with AML/MDS Undergoing Haploidentical Transplantation Yuqian Sun (Peking University People's Hospital, China) | ||
|
[OP03] Oral Presentation 3 |
Room C (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Yoon Seok Choi (College of Medicine, The Catholic University of Korea, Korea) Meerim Park (National Cancer Center, Korea) |
||
| Speaker(s) | 09:00-09:10 | Discovery of a Novel Quiescence-Associated Marker of Top-Tier Hematopoietic Stem Cells in Umbilical Cord Blood by Transcriptomic Profiling Dong-Yeop Shin (Seoul National University College of Medicine, Korea) | |
| 09:10-09:20 | Ectopic EBV Infection in T Cells Identifies Reduced Therapeutic Responsiveness and Immune Dysfunction after Allogeneic Hematopoietic Stem Cell Transplantation Zhifan Zhao (Peking University, China) | ||
| 09:20-09:30 | An Integrated Single-Cell Atlas of Acute Lymphoblastic Leukemia Defines Malignant-Core State Architecture across Clinical and Molecular Contexts Javad Alizargar (National Taipei University of Nursing, Taiwan) | ||
| 09:30-09:40 | HLA Structural Profiles Identified by Protein Language Models Predict Graft Failure in Haploidentical Transplantation Rui Ma (Peking University People's Hospital, China) | ||
| 09:40-09:50 | Tumor Necrosis Factor is a Growth Factor for Mesenchymal Stromal Progenitor Cells Aleksei Bigildeev (Moscow Institute of Physics and Technology, Russia) | ||
| 09:50-10:00 | Optimization of Third–Party–derived Virus–Specific T Cell Manufacturing Using L-Arginine Supplementation and γδT Cell Restimulation Takahiro Tomoda (Institute of Science Tokyo, Japan) | ||
|
[OP04] Oral Presentation 4 |
Room D (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 17 (Thu), 09:00-10:00 | ||
| Chair(s) |
Seong Hyun Jeong (Ajou University School of Medicine, Korea) Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea) |
||
| Speaker(s) | 09:00-09:10 | Model-Predicted Antithymocyte Globulin Exposure and Clinical Outcomes after Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Acute Myeloid Leukemia Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | Older Matched Sibling Donors Remain a Favorable Option in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia: Impact of Donor Age across Donor Types So Yeon Park (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:20-09:30 | Pegylated versus Daily G-CSF for Peripheral Blood Stem Cell Mobilization in Allogeneic Hematopoietic Cell Transplantation Donors Ryo Sato (Yamagata University, Japan) | ||
| 09:30-09:40 | Sequential Haploidentical-Cord Blood Hematopoietic Stem-Cell Transplantation with PT-Cy/Flu in Pediatric Acute Leukemia Zhilin Hu (Shenzhen Children's Hospital, China) | ||
| 09:40-09:50 | The Comparison of Bone Marrow plus Peripheral Blood versus Peripheral Blood as Graft Source in Haploidentical Stem Cell Transplantation for Older Patients Yi Liao (Peking University People's Hospital, China) | ||
| 09:50-10:00 | Successful Multi-Modal Management of Refractory CMV-Associated Hemophagocytic Lymphohistiocytosis and Idiopathic Pneumonia Syndrome Following HLA-Mismatched Bone Marrow Transplantation for Severe Aplastic Anemia Yuichi Kobayashi (Chiba University, Japan) | ||
|
Plenary Session 1 CAR T Cell Therapy Sep. 17 (Thu), 10:30-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL
Children's Hospital of Philadelphia, USA
A New Era of Sequential CAR‑T and Allogeneic HSCT
The First Affiliated Hospital, Zhejiang University School of Medicine, China
|
Luncheon Symposium 1 Sep. 17 (Thu), 12:00-12:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Optimizing cGVHD Management After Ruxolitinib Failure: The Role of Belumosudil in Clinical Practice
The First Affiliated Hospital of Soochow University, China
|
Luncheon Symposium 2 Sep. 17 (Thu), 12:00-12:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) | |
Maintaining Relative Dose Intensity in Elderly DLBCL: Clinical Strategies with Pegfilgrastim
Seoul National University Hospital, Korea
|
Luncheon Symposium 3 Sep. 17 (Thu), 12:00-12:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) | |
Optimizing PNH Management with Iptacopan: Insights from Real-World Practice
College of Medicine, The Catholic University of Korea, Korea
|
Plenary Session 2 GVHD Sep. 17 (Thu), 13:00-14:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Beyond Immunosuppression: Enhancing Tissue Tolerance to Mitigate GVHD through Nutritional Immunity
Dan L. Duncan Comprehensive Cancer Center, USA
Immunologic Mechanisms and Modulation of Chronic Graft-Versus-Host Disease (GVHD)
University of Minnesota, USA
|
Joint Symposium 1 (ASTCT-KSBMT) Evolving T-Cell Manipulation Strategies: Optimization of PTCy and New Frontiers in T-Cell Depletion Sep. 17 (Thu), 14:30-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hyeon-Seok Eom (National Cancer Center, Korea) Margaret MacMillan (University of Minnesota, USA) |
|
Advances in Ex Vivo T Cell Depletion
University of Minnesota, USA
Selective T Cell Depletion and Enrichment
Fred Hutchinson Cancer Center, USA
Optimizing T-Cell Modulation in Adult ALL Transplantation ; ATG, PTCy, and Donor-Specific GVHD Control
College of Medicine, The Catholic University of Korea, Korea
|
Scientific Session 1 Next-Generation Immune Effector Cell Therapies: Emerging Platforms and Biological Insights Sep. 17 (Thu), 14:30-16:00 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea) |
|
Spatially Confined IL-12 Programs CAR-NK through mTORC1 to Coordinate Antitumor Immune Networks
Dana-Farber Cancer Institute, USA
In Vivo CAR-T Therapy: A Paradigm Shift Toward Ready-to-Use Cancer Immunotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Overcoming Resistance in T-Cell Malignancies: From Phase 1 Study of CD5-Targeted Allogeneic CAR-NK Cells
University of Ulsan College of Medicine, Korea
|
Scientific Session 2 Advances in Immunotherapy and Transplant Strategies in Pediatric Hematologic Malignancies Sep. 17 (Thu), 14:30-16:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea) Jun Eun Park (Korea University College of Medicine, Korea) |
|
Virus-Specific T Cells for Adoptive Immunotherapy
Dana-Farber Cancer Institute, USA
Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL
Wroclaw Medical University, Poland
Clinical Applications of Donor Lymphocyte Infusion in Pediatric Malignancies
Sungkyunkwan University School of Medicine, Korea
|
Education Session 1 Additional Cellular Support after Allogeneic Transplantation Sep. 17 (Thu), 14:30-16:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea) Hyoung Soo Choi (Seoul National University College of Medicine, Korea) |
|
Management of Poor Graft Function in Children
Korea University College of Medicine, Korea
Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs
University of Ulsan College of Medicine, Korea
Cellular Support Beyond the Graft – The Continuing Promise of Umbilical Cord Blood Grafts
Case Western Reserve University School of Medicine, USA
|
Joint Symposium 2 (EBMT-KSBMT) Evolving Donor Issues in Allogeneic HSCT: From HLA Matching to Germline Screening and Emerging Concerns Sep. 17 (Thu), 16:50-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Ibrahim Yakoub-Agha (Lille University Hospital, France) |
|
Germline Traits and Donor Selection for Allo-HCT: on Overview and the Paradigm of DDX41
University of Tor Vergata, Italy
Which Donor Should We Use in the Absence of a Matched Sibling in Aplastic Anemia?
La Fe University and Polytechnic Hospital, Spain
Clonal Hematopoiesis in Hematopoietic Stem Cell Transplantation
Seoul National University College of Medicine, Korea
Hematopoietic Stem Cell Donor Selection in 2026: Evolving Perspectives and Current Challenges
University of Ulsan College of Medicine, Korea
|
Scientific Session 3 Post-Transplant Residual Disease in Acute Leukemia: Monitoring and Therapeutic Strategies Sep. 17 (Thu), 16:50-18:20 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Myungshin Kim (The Catholic University of Korea, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea) |
|
Flow Cytometric MRD for AML: Updates in 2026
Amsterdam UMC, The Netherlands
Targeting Residual Disease after Transplant: The Convergence of HCT and Engineered Cellular Therapies
Columbia University Medical Center, USA
Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients
Yonsei University College of Medicine, Korea
|
Scientific Session 4 Science Behind Treatment Response and Relapse Sep. 17 (Thu), 16:50-18:20 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Won-Sik Lee (Inje University College of Medicine, Korea) Sung-Soo Yoon (Kyung Hee University College of Medicine, Korea) |
|
Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML
UNIST, Korea
Improving Post-Transplant Immunological Outcome in AML by Modulating VISTA
Vanderbilt University Medical Center, USA
Immune Escape as a Mechanism of Post-Transplant Relapse
Taussig Cancer Institute, USA
|
Satellite Symposium 1 Sep. 18 (Fri), 08:30-09:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Sung-Yong Kim (Konkuk University School of Medicine, Korea) | |
Triple Targeting in Myelofibrosis with Momelotinib: An Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition
Soonchunhyang University Seoul Hospital, Korea
|
Satellite Symposium 2 Sep. 18 (Fri), 08:30-09:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea) | |
Immune Reconstitution and Infection Prevention After CAR T-Cell and Bispecific Antibody Therapies: The Evolving Role of IVIG
Seoul National University College of Medicine, Korea
|
[OP05] Oral Presentation 5 |
Room A (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Young Hoon Park (Ewha Womans University College of Medicine, Korea) Yu Ri Kim (Yonsei University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Development of FcRH5 as a Therapeutic Target in B-Cell Lymphoma Jeonghwa Kim (Seoul National University College of Medicine, Korea) | |
| 09:10-09:20 | Longitudinal Whole-Exome Sequencing Revealed Early Clonal Suppression and Delayed Resistance Evolution in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Ibrutinib Ho Cheol Jang (Chonnam National University Medical School, Korea) | ||
| 09:20-09:30 | Capturing the Landscape of Electronic Patient-Reported Outcomes during First-Line Lymphoma Therapy: A Multicenter Prospective Study Kunye Kwak (Korea University College of Medicine, Korea) | ||
| 09:30-09:40 | Real-World Outcomes of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL): A Taiwanese Multicenter Case Series Chiayu Chen (China Medical University Hospital, Taiwan) | ||
| 09:40-09:50 | Overcoming Poor Prognosis in Post-CAR-T Relapse: Potential Utility of Bispecific Antibodies and Allogeneic Hematopoietic Stem Cell Transplantation as Effective Salvage Strategies Gi June Min (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:50-10:00 | Prior Bruton Tyrosine Kinase Inhibitor Exposure Is Associated with Inferior Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Mantle Cell Lymphoma Tong-Yoon Kim (College of Medicine, The Catholic University of Korea, Korea) | ||
|
[OP06] Oral Presentation 6 |
Room B (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Chul Won Choi (Korea University College of Medicine, Korea) Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea) |
||
| Speaker(s) | 09:00-09:10 | Risk Stratification for Allogeneic Transplantation in Myelofibrosis: MTSS versus AlloRisk and the Impact of Driver Mutation Clearance Yu-Sung Chang (National Taiwan University Hospital, Taiwan) | |
| 09:10-09:20 | The Role of Pretransplant Cytoreductive Therapy in Patients with Chronic Myelomonocytic Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation Jin Zhang (Peking University People's Hospital, China) | ||
| 09:20-09:30 | Droplet Digital PCR Monitoring of JAK2V617F Complements Donor Chimerism after Allo-HSCT for Myelofibrosis So Yeon Park (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:30-09:40 | Linking Baseline Transcriptomics to Hematopoietic Recovery and Poor Graft Function after Allogeneic Transplantation for Myelofibrosis Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:40-09:50 | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Myelofibrosis: a Chinese Multicenter Retrospective Study Yuqian Sun (Peking University People's Hospital, China) | ||
| 09:50-10:00 | Clinico-Demographic and Hematological Characteristics of Patients with Polycythemia Vera: A Prospective Study in Tertiary Care Center in Nepal Suraj Aryal (Fishtail Hospital and Research Center Pvt Ltd, Nepal) | ||
|
[OP07] Oral Presentation 7 |
Room C (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Ho-Young Yhim (Jeonbuk National University Medical School, Korea) Hyo Jung Kim (Hallym University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65-69 Years Jung Yeon Lee (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | One Thousand Autologous Stem Cell Transplants for Multiple Myeloma: Single Center, Retrospective Analysis Jun Ho Yi (Sungkyunkwan University School of Medicine, Korea) | ||
| 09:20-09:30 | Decoding the Role of TANGO1 in Myeloma Proteostasis and Therapeutic Vulnerability Ji Eun Lee (Yonsei University College of Medicine, Korea) | ||
| 09:30-09:40 | Long-Term Follow-Up of Busulfan plus Cyclophosphamide and Etoposide versus High-Dose Melphalan as Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Sungnam Lim (Inje University College of Medicine, Korea) | ||
| 09:40-09:50 | Impact of Acute GVHD and Delayed Hematopoietic Recovery on the Incidence and Clinical Burden of Late Cytomegalovirus Reactivation and Disease after Letermovir Prophylaxis in CBT Naoki Okada (Kurashiki Central Hospital, Japan) | ||
| 09:50-10:00 | Clinical and Basic Studies of Anti-CD25 Monoclonal Antibody for the Prevention of Acute Graft-versus-Host Disease Yanfei Lu (The First Affiliated Hospital of Guangxi Medical University, China) | ||
|
[OP08] Oral Presentation 8 |
Room D (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Jeong A Park (Inha University College of Medicine, Korea) Min Kyoung Kim (Yeungnam University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Letermovir for Cytomegalovirus Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Results of the LETreal Study Yi Xia (Peking University People's Hospital, China) | |
| 09:10-09:20 | Real-World Analysis of Belumosudil in Chronic Graft-versus-Host Disease: Early Progression May Reflect Ruxolitinib Discontinuation-Associated Flare Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:20-09:30 | Not All High-Risk Features Are Created Equal: Organ- and Subtype-Specific Determinants of Non-Relapse Mortality in TA-TMA Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:30-09:40 | Targeting Steroid-Refractory Chronic GVHD with Reduced-Dose Rituximab Biosimilar (Truxima): A Phase 2 Prospective Study Eunice Jinsol Lee (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:40-09:50 | Letermovir Prophylaxis Real World Data on Cytomegalovirus Reactivation in Paediatric Haematopoietic Stem Cell Transplantation Recipients: A Single-Centre Experience Krithika Krishnakumar (Apollo Cancer Center, India) | ||
| 09:50-10:00 | Hyperacute Fatal Transplant-Associated Thrombotic Microangiopathy with Catastrophic Central Nervous System Involvement after HLA-Matched Sibling Transplantation for Severe Aplastic Anemia Moeko Hino (Chiba University Hospital, Japan) | ||
|
Joint Symposium 3 (East Asia Collaborative Session) The CAR-T Landscape in East Asia: Approvals, Coverage, Domestic Development, and Regulatory Frameworks for Cell and Gene Therapy Sep. 18 (Fri), 10:10-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hyeon-Seok Eom (National Cancer Center, Korea) Su-Peng Yeh (China Medical University Hospital, Taiwan) |
|
Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions
National Clinical Research Center for Hematologic Disease, China
Chimeric Antigen Receptor T-Cell Therapy for Lymphoma in Korea: Current Status, Challenges, and Future Directions
University of Ulsan College of Medicine, Korea
Unlocking Access of CAR-T Therapy in Taiwan: From Dual-Track Regulatory Transformation to National Insurance Breakthroughs
National Taiwan University Cancer Center, Taiwan
Current Status and Challenges of CAR-T Cell Products in Japan: A Regulatory Perspective
Pharmaceuticals and Medical Devices Agency, Japan
|
Scientific Session 5 AML/MDS Biology Sep. 18 (Fri), 10:10-11:40 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Hawk Kim (Ewha Womans University College of Medicine, Korea) Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) |
|
Leukemic Stem Cells in AML: Mechanisms, Detection, and Therapeutic Targeting
New York University Grossman School of Medicine, USA
Single-Cell Genomics for Predicting and Dissecting Venetoclax Resistance in Monocytic AML
Moffitt Cancer Center & Research Institute, USA
Information-Driven Studies on AML
College of Pharmacy, Seoul National University, Korea
|
Scientific Session 6 Potential Role of AI in Hematology and Cellular Therapy Sep. 18 (Fri), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea) |
|
AI-Driven Prediction of Transplant Outcomes
University Hospitals Bochum and Essen, Germany
AI-Based Prediction of Early Relapse after CAR-T Therapy
University of California, San Francisco, USA
Clinical Relevance of BM Fibrosis in MDS Using Digital Imaging Approaches
Seoul National University College of Medicine, Korea
|
Education Session 2 Toxicities of Transplant and Immunotherapy Sep. 18 (Fri), 10:10-11:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Hyeon Jin Park (National Cancer Center, Korea) |
|
Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT
Seoul National University College of Medicine, Korea
Best Anti-Fungal Prophylaxis and Treatment Pre-/Post-HSCT
The Catholic University of Korea, Korea
Management of CAR T Toxicities – Expert Opinion
Children's Hospital of Philadelphia, USA
|
Luncheon Symposium 4 Sep. 18 (Fri), 12:00-12:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) | |
How Deep Responses Translate into Transplant Success and Long-Term Survival in Secondary AML
Seoul National University College of Medicine, Korea
|
Luncheon Symposium 5 Sep. 18 (Fri), 12:00-12:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Kihyun Kim (Sungkyunkwan University School of Medicine, Korea) | |
Unlocking the Clinical Value of Early CAR-T Therapy in Multiple Myeloma: Insights from the CARTITUDE-4 Experience
Seoul National University College of Medicine, Korea
|
Luncheon Symposium 6 Sep. 18 (Fri), 12:00-12:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
CMV Prophylaxis in Pediatric HSCT: An Update on Evidence and Clinical Practice
Sungkyunkwan University School of Medicine, Korea
|
Joint Symposium 4 (ISCT-KSBMT) Next-Generation Immune Cell Therapies Beyond CAR-T Sep. 18 (Fri), 13:00-14:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Je-Jung Lee (Chonnam National University Medical School, Korea) William Hwang (National Cancer Centre Singapore and Singapore General Hospital, Singapore) |
|
Beyond CAR-T: Next-Generation Immune Cell Therapies and New Manufacturing Paradigms
National Cancer Centre Singapore and Singapore General Hospital, Singapore
Fine-Tuning Signal Strength in CD5 CAR-NK Cells for Targeted T Cell Cancer Therapy
College of Pharmacy, Yonsei University, Korea
Multispecific T Cell Engagers, γδ T Cells, and NK Cell–Based Immunotherapy
University of Ulsan College of Medicine, Korea
|
Scientific Session 7 Expanding CAR T-Cell Therapy beyond Lymphoid Malignancies: Myeloid Neoplasms, Solid Tumors, and Autoimmune Diseases Sep. 18 (Fri), 13:00-14:30 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
June-Won Cheong (Yonsei University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea) |
|
Clinical Translation of Next-Generation Cellular Therapies for Acute Myeloid Leukemia: From Clinical Proof-of-Concept to Hematopoietic Stem Cell–Sparing Immunotherapy
Memorial Sloan Kettering Cancer Center, USA
Enhanced CAR-T Cell Therapy Using Novel Gene Modifications
Seoul National University College of Medicine, Korea
Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases
Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
|
Nursing Session 1 KOR Multidisciplinary Approach to Hematopoietic Stem Cell Transplantation Patients I Sep. 18 (Fri), 13:00-14:30 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | EunJung Joo (National Cancer Center, Korea) | |
Ocular Diseases in Hematopoietic Stem Cell Transplantation Patients: Key Indicators for Immediate Recognition
National Cancer Center, Korea
From Diagnostics to Intervention: Managing Infections in Hematology Patients Based on Imaging and Lab Results
College of Medicine, The Catholic University of Korea, Korea
|
Education Session 3 Practical Issues in Stem Cell Transplantation 2026 Sep. 18 (Fri), 13:00-14:30 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Yong Park (Korea University College of Medicine, Korea) |
|
Recent Trends in Conditioning Regimens for Myeloid Malignancies
Chungnam National University College of Medicine, Korea
PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG
Gregorio Marañón University General Hospital, Spain
Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide
Seoul National University College of Medicine, Korea
|
Presidential Symposium Lymphoma Cell Therapy Sep. 18 (Fri), 14:40-15:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hyeon-Seok Eom (National Cancer Center, Korea) | |
Evolution of Cellular Therapies in Management of Lymphoma Patients
University of Pennsylvania, USA
|
Plenary Session 3 HSCT for Non-Malignant Disease Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ho Joon Im (University of Ulsan College of Medicine, Korea) | |
Management of Mixed Chimerism and Graft Failure in Non-Malignant Diseases
Dana-Farber Cancer Institute, USA
|
Debate Session 1 KOR Allogeneic HSCT in Patients with AML or MDS with TP53 Alternation Sep. 18 (Fri), 16:50-17:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Joon Ho Moon (Kyungpook National University School of Medicine, Korea) | |
To Transplant
Chonnam National University Medical School, Korea
Not to Transplant
Yonsei University College of Medicine, Korea
|
Debate Session 2 KOR HSCT for HLH: Decreased Conditioning Intensity vs. Increased Conditioning Intensity Sep. 18 (Fri), 17:40-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) | |
Reduced Intensity Conditioning
Seoul National University College of Medicine, Korea
Myeloablative Conditioning
Chonnam National University Hwasun Hospital, Korea
|
Joint Symposium 5 (JSTCT-KSBMT) EBV-Associated Diseases and HSCT: From CAEBV to Post-Transplant Complications Sep. 18 (Fri), 16:50-18:30 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Takanori Teshima (Hokkaido University, Japan) |
|
EBV-Positive T/NK-Cell and B-Cell Lymphoproliferative Diseases: HSCT as Cure and as Complication
Sungkyunkwan University School of Medicine, Korea
Clinicopathological Spectrum of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
Seoul National University College of Medicine, Korea
Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcomes from Japanese Nationwide Data
Kameda Medical Center, Japan
A Japanese Registry-Based Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis
Keio University, Japan
|
Scientific Session 8 Advances in HSCT Conditioning Sep. 18 (Fri), 16:50-18:20 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea) |
|
Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in 2026
Fred Hutchinson Cancer Center, USA
Selection of Allogeneic Hematopoietic Progenitor Cell Donors
Memorial Sloan Kettering Cancer Center, USA
Optimal Conditioning in Autologous HSCT: Focus on Lymphoma
Seoul National University College of Medicine, Korea
|
Satellite Symposium 3 Sep. 19 (Sat), 08:30-09:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Seok Lee (Ewha Womans University College of Medicine, Korea) | |
Ph-Positive ALL in 2026: From Precision Immuno-Targeted Therapy to Transplantation
College of Medicine, The Catholic University of Korea, Korea
|
Joint Symposium 6 (TSBMT-KSBMT) Endothelial Dysfunction Syndromes after Allogeneic HSCT: From SOS/VOD and TA-TMA to CLS/ES and PRES Sep. 19 (Sat), 09:00-10:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) Hakan Göker (Hacettepe University, Türkiye) |
|
Hepatic, Pulmonary, and Systemic Endothelial Injury after Allogeneic HSCT: SOS/VOD, Capillary Leak/Engraftment Syndrome, and IPS/DAH
Hacettepe University, Türkiye
Transplant-Associated Thrombotic Microangiopathy, PRES, and GVHD-Related Endothelial Injury after Allogeneic HSCT
Korea University College of Medicine, Korea
|
[OP09] Oral Presentation 9 |
Room C (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 19 (Sat), 09:00-10:00 | ||
| Chair(s) |
Jae Min Lee (Pusan National University School of Medicine, Korea) Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Real-World Outcomes of Chimeric Antigen Receptor T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Role of Consolidative Hematopoietic Cell Transplantation Jae Won Yoo (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | Longitudinal Immune Reconstitution and Viral Landscape under Letermovir Prophylaxis in Pediatric Allogeneic HSCT Qingwei Wang (Children's Hospital of Soochow University, China) | ||
| 09:20-09:30 | Outcomes of Ex Vivo T Cell Depleted Haploidentical HSCT in Children with Acute Lymphoblastic Leukemia Sung Han Kang (University of Ulsan College of Medicine, Korea) | ||
| 09:30-09:40 | Comparative Outcomes of Carboplatin-Etoposide-Melphalan and Busulfan-Melphalan as High-Dose Chemotherapy for High-Risk Neuroblastoma: An International Two-Center Study from Taiwan and Korea Jin Kyung Suh (Seoul National University College of Medicine, Korea) | ||
| 09:40-09:50 | Haploidentical Transplantation with Unrelated Cord Blood Support (SZ-19-TM Protocol) Improves Outcomes in Pediatric Transfusion-Dependent Thalassemia: A Large-Scale Retrospective Cohort Study Ruihao Zheng (Shenzhen Children's Hospital, China) | ||
| 09:50-10:00 | Pre-Freezing Hematocrit Independently Associated with Post-Thaw CD34+ Cell Viability in Cryopreserved Autologous Peripheral Blood Stem Cell Products from Pediatric Neuroblastoma Patients Thi Thanh Lam Nguyen (National Children's Hospital, Vietnam) | ||
|
[OP010] Oral Presentation 10 |
Room D (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 19 (Sat), 09:00-10:00 | ||
| Chair(s) |
Ho Sup Lee (Kosin University College of Medicine, Korea) Jee Hyun Kong (Wonju Severance Christian Hospital, Korea) |
||
| Speaker(s) | 09:00-09:10 | Single-Cell Transcriptomic and TCR Repertoire Profiling Defines an Exhaustion-Associated CD39+ CD8+ T-Cell State in the Bone Marrow of Acute Lymphoblastic Leukemia Nayeon Seong (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | Assessment of CRS-Related Toxicity of BCMA CAR-MILs Using the NSG-SGM3 Model Manh Cuong Vo (Chonnam National University Medical School, Korea) | ||
| 09:20-09:30 | Development of Bispecific CAR- T Cells Targeting Mesothelin (MSLN) and Disialoganglioside 2 (GD2) for Neuroblastoma Nayoung Kim (University of Ulsan College of Medicine, Korea) | ||
| 09:30-09:40 | First-in-Human Phase 1 Study of GF-CART01, a Non-Viral CD19/CD20 Dual-Targeting CAR T Generated Using the qCART Platform in Relapsed/Refractory B-Cell Malignancies Shang-Ju Wu (National Taiwan University Hospital, Taiwan) | ||
| 09:40-09:50 | Exploring the Therapeutic Potential of CAR-MSCs Targeting the OX40/OX40L Axis in Immune Disorders Byungchan Kim (Sungkyunkwan University School of Medicine, Korea) | ||
| 09:50-10:00 | First Korean Report of Donor-Derived Multivirus-Specific T-Cell Therapy for Refractory BK Virus Hemorrhagic Cystitis after Pediatric Haploidentical Hematopoietic Cell Transplantation Jae Won Yoo (College of Medicine, The Catholic University of Korea, Korea) | ||
|
Scientific Session 9 Insights on GVHD Prediction, Prevention and Management Sep. 19 (Sat), 10:10-11:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hoon Kook (Chonnam National University Medical School, Korea) Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) |
|
Pediatric Chronic GVHD: From Biological Insights to Clinical Management
BC Children's Hospital Research Institute, Canada
Immunobiology of GVHD Prevention
Hokkaido University, Japan
Microbiome and GvHD Following Allogeneic HSCT
University of Ulsan College of Medicine, Korea
|
Scientific Session 10 Immune Effector Cell Therapy in Lymphoid Malignancies: From Pivotal Trials to Real-World Practice Sep. 19 (Sat), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Jin Seok Kim (Yonsei University College of Medicine, Korea) Young Rok Do (Keimyung University School of Medicine, Korea) |
|
Integrating MRD into CAR T-Cell Therapy for ALL: From Patient Selection to Post-Treatment Intervention
Memorial Sloan Kettering Cancer Center, USA
Sequencing Cellular Therapy in Multiple Myeloma: Lessons from Trials and Real-World Practice
Medical College of Wisconsin, USA
Real-World CAR‑T Experience in LBCL
College of Medicine, The Catholic University of Korea, Korea
|
Nursing Session 2 KOR Multidisciplinary Approach to Hematopoietic Stem Cell Transplantation Patients II & Thirty Years of Hematopoietic Stem Cell Transplant Nursing: Past, Present and Future Sep. 19 (Sat), 10:10-11:10 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Heejun Kim (Samsung Medical Center, Korea) | |
Radiotherapy in Hematologic Malignancies and Stem Cell Transplantation
National Cancer Center, Korea
Restoring Normal Life for Hematology Patients
College of Medicine, The Catholic University of Korea, Korea
